MX2018000016A - Composiciones farmaceuticas liofilizadas. - Google Patents

Composiciones farmaceuticas liofilizadas.

Info

Publication number
MX2018000016A
MX2018000016A MX2018000016A MX2018000016A MX2018000016A MX 2018000016 A MX2018000016 A MX 2018000016A MX 2018000016 A MX2018000016 A MX 2018000016A MX 2018000016 A MX2018000016 A MX 2018000016A MX 2018000016 A MX2018000016 A MX 2018000016A
Authority
MX
Mexico
Prior art keywords
lyophilized pharmaceutical
pharmaceutical compositions
solvents
solvent
compound
Prior art date
Application number
MX2018000016A
Other languages
English (en)
Inventor
Redkar Sanjeev
Joshi-Hangal Rajashree
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of MX2018000016A publication Critical patent/MX2018000016A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/02—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atoms
    • A01N43/04—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atoms with one hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F26—DRYING
    • F26B—DRYING SOLID MATERIALS OR OBJECTS BY REMOVING LIQUID THEREFROM
    • F26B5/00—Drying solid materials or objects by processes not involving the application of heat
    • F26B5/04—Drying solid materials or objects by processes not involving the application of heat by evaporation or sublimation of moisture under reduced pressure, e.g. in a vacuum
    • F26B5/06—Drying solid materials or objects by processes not involving the application of heat by evaporation or sublimation of moisture under reduced pressure, e.g. in a vacuum the process involving freezing
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F26—DRYING
    • F26B—DRYING SOLID MATERIALS OR OBJECTS BY REMOVING LIQUID THEREFROM
    • F26B5/00—Drying solid materials or objects by processes not involving the application of heat
    • F26B5/08—Drying solid materials or objects by processes not involving the application of heat by centrifugal treatment
    • F26B5/10—Drying solid materials or objects by processes not involving the application of heat by centrifugal treatment the process involving freezing

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Mechanical Engineering (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Dentistry (AREA)
  • Pest Control & Pesticides (AREA)
  • Plant Pathology (AREA)
  • Agronomy & Crop Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención proporciona un método para preparar una composición farmacéutica liofilizada que contiene un compuesto descrito en la presente o una sal farmacéuticamente aceptable del mismo. EL proceso comprende disolver el compuesto en un solvente que comprende dimetilsulfóxido y opcionalmente uno o más co-solventes para formar una solución, y luego remover el solvente y cualquiera de los cosolventes por un proceso de secado por congelación. También proporcionadas por la invención son composiciones farmacéuticas liofilizadas y su uso en medicina y en particular en el tratamiento de cáncer.
MX2018000016A 2015-07-02 2016-07-01 Composiciones farmaceuticas liofilizadas. MX2018000016A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562188025P 2015-07-02 2015-07-02
PCT/US2016/040730 WO2017004538A1 (en) 2015-07-02 2016-07-01 Lyophilized pharmaceutical compositions

Publications (1)

Publication Number Publication Date
MX2018000016A true MX2018000016A (es) 2019-01-31

Family

ID=57609219

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018000016A MX2018000016A (es) 2015-07-02 2016-07-01 Composiciones farmaceuticas liofilizadas.

Country Status (15)

Country Link
US (3) US10485764B2 (es)
EP (1) EP3316685A4 (es)
JP (1) JP6768722B2 (es)
KR (1) KR20180024010A (es)
CN (1) CN108024535A (es)
AU (1) AU2016287585B2 (es)
BR (1) BR112018000054A2 (es)
CA (1) CA2991167A1 (es)
HK (1) HK1254645A1 (es)
IL (1) IL256686A (es)
MX (1) MX2018000016A (es)
PH (1) PH12017550152A1 (es)
RU (1) RU2723590C2 (es)
WO (1) WO2017004538A1 (es)
ZA (1) ZA201800487B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7700567B2 (en) 2005-09-29 2010-04-20 Supergen, Inc. Oligonucleotide analogues incorporating 5-aza-cytosine therein
CN103945902B (zh) 2011-08-30 2018-07-20 阿斯泰克斯制药公司 地西他滨衍生物制剂
AU2016287585B2 (en) * 2015-07-02 2020-12-17 Otsuka Pharmaceutical Co., Ltd. Lyophilized pharmaceutical compositions
GB201704965D0 (en) 2017-03-28 2017-05-10 Astex Therapeutics Ltd Pharmaceutical compounds
GB201704966D0 (en) * 2017-03-28 2017-05-10 Astex Therapeutics Ltd Pharmaceutical compounds
GB2564481B (en) * 2017-07-14 2019-10-23 4D Pharma Leon S L U Process
JP2020529409A (ja) 2017-08-03 2020-10-08 大塚製薬株式会社 薬物化合物およびその精製方法
WO2021075423A1 (ja) * 2019-10-18 2021-04-22 富士フイルム和光純薬株式会社 ホスホロアミダイト活性化剤
IL295221A (en) * 2020-02-04 2022-10-01 Regeneron Pharma Target residual moisture content for a lyophilic drug product
CN111956670A (zh) * 2020-08-31 2020-11-20 杭州伊瑟奇生物科技有限公司 一种间充质干细胞及其活性因子复合物冻干品的制备方法
US11287185B1 (en) 2020-09-09 2022-03-29 Stay Fresh Technology, LLC Freeze drying with constant-pressure and constant-temperature phases
CN116157141A (zh) * 2020-09-14 2023-05-23 美国安进公司 制备冻干蛋白配制品的方法

Family Cites Families (131)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH527207A (de) 1968-05-08 1972-08-31 Ceskoslovenska Akademie Ved Verfahren zur Herstellung von 1-Glycosyl-5-azacytosinen
DE2105468A1 (en) 1970-04-23 1971-11-18 Czeskoslovenska akademie ved, Prag; VtnKarstedt, E., Dipl.-Ing. Dr., Pat-Anw., 4200 Oberhausen 1-glycosyl-5-aza-cytosines prepn
US5157120A (en) 1980-09-16 1992-10-20 Syntex (U.S.A.) Inc. Guanine derivatives
US4534899A (en) 1981-07-20 1985-08-13 Lipid Specialties, Inc. Synthetic phospholipid compounds
US4426330A (en) 1981-07-20 1984-01-17 Lipid Specialties, Inc. Synthetic phospholipid compounds
US4855304A (en) 1985-01-10 1989-08-08 Repligen Corporation Dinucleoside pyrophosphates and pyrophosphate homologs as plant antivirals
JPS61176523A (ja) 1985-01-30 1986-08-08 Teruhiko Beppu 制癌剤
GB8612826D0 (en) 1986-05-27 1986-07-02 Boots Co Plc Insecticidal compositions
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US4920016A (en) 1986-12-24 1990-04-24 Linear Technology, Inc. Liposomes with enhanced circulation time
DE3712786A1 (de) 1987-04-15 1988-11-03 Merck Patent Gmbh Verfahren und mittel zur bestimmung von nucleinsaeuren
CS269077B1 (cs) 1987-10-01 1990-04-11 Piskala Alois Způsob přípravy 5-azacytosinů
US5736531A (en) 1987-10-28 1998-04-07 Pro-Neuron, Inc. Compositions of chemotherapeutic agent or antiviral agent with acylated pyrimidine nucleosides
US5968914A (en) 1987-10-28 1999-10-19 Pro-Neuron, Inc. Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides
US4904770A (en) 1988-03-24 1990-02-27 Bristol-Myers Company Production of 2',3'-dideoxy-2',3'-didehydronucleosides
US5324831A (en) 1988-04-06 1994-06-28 The United States Of America As Represented By The Secretary Of Health And Human Services Phosphoramidite reagent for chemical synthesis of modified DNA
GB8824593D0 (en) 1988-10-20 1988-11-23 Royal Free Hosp School Med Liposomes
PT93772A (pt) 1989-04-17 1991-01-08 Searle & Co Processo para a preparacao de composicoes para o tratamento de neoplasias, contendo um agente anti-neoplastico, por exemplo doxorubicina e um agente protector para reduzir os efeitos secundarios, por exemplo carbetimer
US5225212A (en) 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
US5356633A (en) 1989-10-20 1994-10-18 Liposome Technology, Inc. Method of treatment of inflamed tissues
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5665710A (en) 1990-04-30 1997-09-09 Georgetown University Method of making liposomal oligodeoxynucleotide compositions
US5610289A (en) 1990-07-27 1997-03-11 Isis Pharmaceuticals, Inc. Backbone modified oligonucleotide analogues
ZA923641B (en) 1991-05-21 1993-02-24 Iaf Biochem Int Processes for the diastereoselective synthesis of nucleosides
JP3220180B2 (ja) 1991-05-23 2001-10-22 三菱化学株式会社 薬剤含有タンパク質結合リポソーム
DK0594667T3 (da) 1991-07-05 2001-11-12 Pro Neuron Inc Behandling af kemoterapeutiske og antivirale, aktive stoffers toksiske virkning med acylerede pyrimidinnucleosider
IL103311A0 (en) 1991-10-07 1993-03-15 Univ Johns Hopkins Formation of triple helix complexes of single stranded nucleic acids using nucleoside oligomers
JPH05219974A (ja) 1992-02-13 1993-08-31 Mitsui Petrochem Ind Ltd トロパンアルカロイドの製造方法
JPH05246891A (ja) 1992-03-09 1993-09-24 Kobayashi Seiyaku Kogyo Kk 安定な抗膵炎用注射液
FR2692265B1 (fr) 1992-05-25 1996-11-08 Centre Nat Rech Scient Composes biologiquement actifs de type phosphotriesters.
US5607691A (en) 1992-06-12 1997-03-04 Affymax Technologies N.V. Compositions and methods for enhanced drug delivery
JP3351476B2 (ja) 1993-01-22 2002-11-25 三菱化学株式会社 リン脂質誘導体及びそれを含有するリポソーム
US5395619A (en) 1993-03-03 1995-03-07 Liposome Technology, Inc. Lipid-polymer conjugates and liposomes
FR2705099B1 (fr) 1993-05-12 1995-08-04 Centre Nat Rech Scient Oligonucléotides phosphorothioates triesters et procédé de préparation.
WO1994026761A1 (en) 1993-05-14 1994-11-24 Pro-Neuron, Inc. Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides
GB9311252D0 (en) 1993-06-01 1993-07-21 Hafslund Nycomed As Cell growth regualtors
EP0734436B1 (en) 1993-11-30 1999-04-14 McGILL UNIVERSITY Inhibition of dna methyltransferase
US5540935A (en) 1993-12-06 1996-07-30 Nof Corporation Reactive vesicle and functional substance-fixed vesicle
US6432924B1 (en) 1993-12-26 2002-08-13 East Carolina University Method of treating disorders characterized by overexpression of cytidine deaminase or deoxycytidine deaminase
US5543152A (en) 1994-06-20 1996-08-06 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
US5856090A (en) 1994-09-09 1999-01-05 The Scripps Research Institute DNA-methylase linking reaction
US5820873A (en) 1994-09-30 1998-10-13 The University Of British Columbia Polyethylene glycol modified ceramide lipids and liposome uses thereof
US20030104576A1 (en) 1994-10-07 2003-06-05 Jonathan W. Nyce Dna construct, composition, formulations & methods for making the construct & for modulating expression
JPH11505422A (ja) 1995-05-19 1999-05-21 フィテラ インク． 植物細胞培養物および植物組織培養物の処理方法
WO1996039035A1 (en) 1995-06-06 1996-12-12 Case Western Reserve University Myogenic differentiation of human mesenchymal stem cells
US5756122A (en) 1995-06-07 1998-05-26 Georgetown University Liposomally encapsulated nucleic acids having high entrapment efficiencies, method of manufacturer and use thereof for transfection of targeted cells
JPH11511128A (ja) 1995-08-01 1999-09-28 ノバルティス・アクチエンゲゼルシャフト リポソームオリゴヌクレオチド組成物
US5858397A (en) 1995-10-11 1999-01-12 University Of British Columbia Liposomal formulations of mitoxantrone
EP0876149A4 (en) 1995-12-22 2001-09-26 Univ East Carolina PROCESS FOR THE TREATMENT OF CHARACTERIZED DISORDERS BY OVEREXPRESSION OF CYTIDINE-DESAMINASE OR DESOXYCYTIDINE-DESAMINASE
SK284054B6 (sk) 1996-10-16 2004-08-03 Icn Pharmaceuticals, Inc. Substituované triazolové nukleozidy, farmaceutický prostriedok s ich obsahom a ich použitie
US6423692B2 (en) 1997-04-24 2002-07-23 Dana-Farber Cancer Institute, Inc. Method of enhancing the effectiveness of DCK phosphorylated molecules
US6153383A (en) 1997-12-09 2000-11-28 Verdine; Gregory L. Synthetic transcriptional modulators and uses thereof
CA2584482C (en) 1998-02-05 2012-03-27 Smithkline Beecham Biologicals S.A. Tumor-associated antigen derivatives from the mage family, and nucleic acid sequences encoding them, used for the preparation of fusion proteins and of compositions for vaccination
EP1123111B1 (en) 1998-10-19 2004-09-15 Methylgene, Inc. Modulation of dna methyltransferase expression by combination therapy
CZ303703B6 (cs) 1998-12-23 2013-03-20 Pfizer Inc. Monoklonální protilátka nebo její antigen-vázající fragment, farmaceutická kompozice obsahující tuto protilátku nebo fragment, bunecná linie produkující tuto protilátku nebo fragment, zpusob prípravy této protilátky, izolovaná nukleová kyselina kóduj
AU3469400A (en) 1999-01-05 2000-07-24 Clarence C. Lee Pharmaceutical compositions for treatment of diseased tissues
WO2000062075A1 (en) 1999-04-13 2000-10-19 Rutgers, The State University Of New Jersey Ubiquitin cross-reactive protein as a prognostic marker for tumor cell chemosensitivity
AU780454B2 (en) 1999-06-03 2005-03-24 Jessie L.S. Au Methods and compositions for modulating cell proliferation and cell death
DE19935303A1 (de) 1999-07-28 2001-02-08 Aventis Pharma Gmbh Oligonukleotide zur Inhibierung der Expression von humanem eg5
EP1792991A1 (en) 1999-08-24 2007-06-06 Medarex, Inc. Human CTLA-4 antibodies and their uses
JP2001163776A (ja) 1999-09-30 2001-06-19 Nisshin Oil Mills Ltd:The 安定化された液剤
AU785115B2 (en) 1999-10-18 2006-09-21 Emory University TMS1 compositions and methods of use
AU2001247444A1 (en) 2000-03-15 2001-09-24 University Of Massachusetts Erbeta-mediated gene expression
CN1460181A (zh) 2000-09-08 2003-12-03 汉城国立大学工业基金会 参与细胞衰老的核酸序列和蛋白质
US6900540B1 (en) 2000-12-07 2005-05-31 Cadence Design Systems, Inc. Simulating diagonal wiring directions using Manhattan directional wires
AU2002219472A1 (en) 2001-01-02 2002-07-16 Elisabeth Shanahan-Prendergast Treatment for inhibiting neoplastic lesions using incensole and/or furanogermacrens
RS50236B (sr) 2001-01-22 2009-07-15 Merck & Co.Inc., Nukleozidni derivati kao inhibitori rnk-zavisne rnk virusne polimeraze
JP2002223753A (ja) 2001-01-30 2002-08-13 Hitachi Ltd 薬物応答解析用オリゴヌクレオチドアレイ
US7205392B2 (en) 2001-02-05 2007-04-17 Innoventus Project Ab Histidine-rich glycoprotein
US6613753B2 (en) 2001-02-21 2003-09-02 Supergen, Inc. Restore cancer-suppressing functions to neoplastic cells through DNA hypomethylation
WO2002069903A2 (en) 2001-03-06 2002-09-12 Biocryst Pharmaceuticals, Inc. Nucleosides, preparation thereof and use as inhibitors of rna viral polymerases
US20060194275A1 (en) 2001-04-13 2006-08-31 Incyte Corporation Transporter and ion channels
US6905669B2 (en) 2001-04-24 2005-06-14 Supergen, Inc. Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase
CN1520297A (zh) 2001-04-26 2004-08-11 ���ߵ���Ƶϵͳ��˾ 包含复合药物(codrugs)的缓释药物传递系统
US20030148973A1 (en) 2001-05-23 2003-08-07 Peter Emtage MAGE-A1 peptides for treating or preventing cancer
AU2002318336A1 (en) 2001-06-08 2002-12-23 U.S. Genomics, Inc. Methods and products for analyzing nucleic acids based on methylation status
JP2002370939A (ja) 2001-06-12 2002-12-24 Taisho Pharmaceut Co Ltd 育毛剤
SE0102627L (sv) 2001-07-27 2002-11-19 Geneinvent Bbl Ab Vektorer motståndskraftiga mot metylering
US20030045497A1 (en) 2001-07-27 2003-03-06 Geneinvent Bbl Ab Methylation resistant vectors
WO2003012085A1 (en) 2001-07-30 2003-02-13 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Antigen presenting cells, method for their preparation and their use for cancer vaccines
ES2334774T3 (es) 2001-09-05 2010-03-16 Chemgenex Pharmaceuticals Limited Tratamiento de la leucemia mielogena cronica, resistente o intoleranteal sti571, que consiste en homoharrigtonina sola o combinada con otros agentes.
US20030158598A1 (en) 2001-09-17 2003-08-21 Control Delivery Systems, Inc. System for sustained-release delivery of anti-inflammatory agents from a coated medical device
IN2014DN10834A (es) 2001-09-17 2015-09-04 Psivida Inc
IL161036A0 (en) 2001-09-24 2004-08-31 Methods and compositions to determine the chemosensitizing dose of suramin used in combination therapy
AU2002342004A1 (en) 2001-10-05 2003-04-22 Case Western Reserve University Methods and compositions for detecting colon cancers
US7132587B2 (en) 2001-11-08 2006-11-07 Agency Of Industrial Science And Technology Non-autonomous transposon gene of rice, transformed plant and method of use
KR20050044570A (ko) 2001-11-23 2005-05-12 추가이 세이야쿠 가부시키가이샤 종양 표적 효소의 동정 방법
JP2005515192A (ja) 2001-11-29 2005-05-26 ダンドリット バイオテック アクティーゼルスカブ ヒト又は動物において免疫応答を誘導するための医薬組成物
AU2002352195A1 (en) 2001-11-30 2003-06-10 Medigene Aktiengesellschaft Optimized production of viral vectors derived from paroviruses in packaging and production cells by hsv infection or treatment with dna methylation inhibitors
GB0201498D0 (en) 2002-01-23 2002-03-13 Biotech Res Ventures Pte Ltd Materials and methods for treating cancer
US6998391B2 (en) 2002-02-07 2006-02-14 Supergen.Inc. Method for treating diseases associated with abnormal kinase activity
US20030147813A1 (en) 2002-02-07 2003-08-07 John Lyons Method for treating chronic myelogenous leukemia
AU2002238874A1 (en) 2002-03-13 2003-09-22 F.Hoffmann-La Roche Ag Method for selecting drug sensitivity-determining factors and method for predicting drug sensitivity using the selected factors
JP2003310293A (ja) 2002-04-26 2003-11-05 Mitsui Chemicals Inc ヌクレオシド化合物の製造法
HUE057124T2 (hu) 2002-05-02 2022-04-28 Wyeth Holdings Llc Calicheamicin származék - hordozó konjugátumok
AU2003251483A1 (en) 2002-06-05 2003-12-22 Case Western Reserve University Methods and compositions for detecting cancers
US6982253B2 (en) 2002-06-05 2006-01-03 Supergen, Inc. Liquid formulation of decitabine and use of the same
AU2003286836A1 (en) 2002-10-31 2004-06-07 Supergen, Inc. Pharmaceutical formulations targeting specific regions of the gastrointestinal tract
US20050037992A1 (en) 2003-07-22 2005-02-17 John Lyons Composition and method for treating neurological disorders
US20050059682A1 (en) 2003-09-12 2005-03-17 Supergen, Inc., A Delaware Corporation Compositions and methods for treatment of cancer
WO2005033278A2 (en) 2003-09-30 2005-04-14 Ludwig Institute For Cancer Research In vivo efficacy of ny-eso-1 plus iscom
US7846436B2 (en) 2003-11-28 2010-12-07 Chemgenes Corporation Oligonucleotides and related compounds
CN1305478C (zh) * 2004-05-12 2007-03-21 天津市资福医药科技开发有限公司 氨磷汀冻干制剂及其制备方法
ES2322172T3 (es) 2004-05-26 2009-06-17 Biovaxim Limited Composiciones que comprenden agentes desmetilantes como potenciadores de la inmunoterapia para el tratamiento de infecciones cronicas y enfermedades neoplasicas y metodos para tratar las mismas.
US20060014949A1 (en) 2004-07-13 2006-01-19 Supergen Inc. Compositions and formulations of decitabine polymorphs and methods of use thereof
US20060069060A1 (en) 2004-09-27 2006-03-30 Sanjeev Redkar Salts of decitabine
US20060063735A1 (en) 2004-09-17 2006-03-23 Supergen, Inc. Salts of 5-azacytidine
BRPI0515735A2 (pt) 2004-11-04 2011-10-11 Pfizer Prod Inc tratamento de combinação de anticorpo de ctla4 e inibidor de aromatase para cáncer de mama, suas composições farmacêuticas e respectivos usos
US20060128653A1 (en) * 2004-12-10 2006-06-15 Chunlin Tang Pharmaceutical formulation of decitabine
US20060128654A1 (en) 2004-12-10 2006-06-15 Chunlin Tang Pharmaceutical formulation of cytidine analogs and derivatives
WO2006071983A2 (en) 2004-12-29 2006-07-06 Mannkind Corporation Use of compositions comprising various tumor-associated antigens as anti-cancer vaccines
US7250416B2 (en) 2005-03-11 2007-07-31 Supergen, Inc. Azacytosine analogs and derivatives
JO2787B1 (en) 2005-04-27 2014-03-15 امجين إنك, Alternative amide derivatives and methods of use
KR101339628B1 (ko) 2005-05-09 2013-12-09 메다렉스, 인코포레이티드 예정 사멸 인자 1(ｐｄ-1)에 대한 인간 모노클로날 항체, 및 항-ｐｄ-1 항체를 단독 사용하거나 기타 면역 요법제와 병용한 암 치료 방법
KR101888321B1 (ko) 2005-07-01 2018-08-13 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
US7700567B2 (en) 2005-09-29 2010-04-20 Supergen, Inc. Oligonucleotide analogues incorporating 5-aza-cytosine therein
US20070105792A1 (en) 2005-11-04 2007-05-10 Dimartino Jorge F Administration Of DNA Methylation Inhibitors For Treating Epigenetic Diseases
US20070117776A1 (en) 2005-11-04 2007-05-24 John Lyons Low Dose Therapy Of DNA Methylation Inhibitors
CN101361718B (zh) 2008-09-26 2013-08-28 深圳万乐药业有限公司 稳定的地西他滨冻干制剂的制备方法
CN101584670B (zh) * 2009-06-19 2011-04-20 江苏奥赛康药业有限公司 地西他滨冻干粉针剂
GB201006096D0 (en) 2010-04-13 2010-05-26 Alligator Bioscience Ab Novel compositions and uses thereof
CA2810668A1 (en) 2010-09-08 2012-03-15 Halozyme, Inc. Methods for assessing and identifying or evolving conditionally active therapeutic proteins
CN102688199B (zh) * 2011-03-23 2013-08-21 重庆莱美药业股份有限公司 地西他滨冻干制剂及其制备方法
US9409987B2 (en) 2011-04-15 2016-08-09 Compugen Ltd Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer
CN102319222B (zh) * 2011-08-12 2013-05-08 齐鲁制药(海南)有限公司 一种地西他滨冻干制剂及其制备方法
CN103945902B (zh) * 2011-08-30 2018-07-20 阿斯泰克斯制药公司 地西他滨衍生物制剂
EP2811984B1 (en) * 2012-02-06 2015-08-26 Fresenius Kabi Oncology Limited Process for preparing stable pharmaceutical compositions of compounds susceptible to hydrolysis
US20140193456A1 (en) * 2013-01-09 2014-07-10 Hristem Mitkov Dyanov Method for Drying-Conservation of Natural Substances
PT2961388T (pt) * 2013-03-01 2019-07-11 Astex Pharmaceuticals Inc Combinações de fármacos
AU2016287585B2 (en) 2015-07-02 2020-12-17 Otsuka Pharmaceutical Co., Ltd. Lyophilized pharmaceutical compositions
JP2020529409A (ja) * 2017-08-03 2020-10-08 大塚製薬株式会社 薬物化合物およびその精製方法

Also Published As

Publication number Publication date
JP6768722B2 (ja) 2020-10-14
RU2723590C2 (ru) 2020-06-16
US20200093748A1 (en) 2020-03-26
US20220016033A1 (en) 2022-01-20
IL256686A (en) 2018-03-29
HK1254645A1 (zh) 2019-07-26
CA2991167A1 (en) 2017-01-05
AU2016287585A1 (en) 2018-02-08
US20170000738A1 (en) 2017-01-05
RU2018103884A3 (es) 2020-01-21
CN108024535A (zh) 2018-05-11
BR112018000054A2 (pt) 2018-09-04
EP3316685A4 (en) 2019-03-13
EP3316685A1 (en) 2018-05-09
ZA201800487B (en) 2020-05-27
US10485764B2 (en) 2019-11-26
RU2018103884A (ru) 2019-08-05
PH12017550152A1 (en) 2018-07-09
AU2016287585B2 (en) 2020-12-17
WO2017004538A1 (en) 2017-01-05
JP2018519330A (ja) 2018-07-19
KR20180024010A (ko) 2018-03-07

Similar Documents

Publication Publication Date Title
PH12017550152A1 (en) Lyophilized pharmaceutical compositions
PH12020550041A1 (en) Drug compound and purification methods thereof
NZ730803A (en) Methods for the preparation of ribosides
EA033266B1 (ru) Гидроксисложноэфирные производные, способ их получения и фармацевтические композиции, содержащие их
MX2016013689A (es) Compuestos 4-amino-imidazoquinolina.
TW201613901A (en) New compounds
MX2023006541A (es) Formulaciones de dosis fija.
TR201901077T4 (tr) Kanser Veya Enfeksiyon Tedavisine Yönelik Birleşik Preparasyonlar
MX2016012574A (es) Compuestos heteroarilo sustituidos y metodos de uso.
HK1231416A1 (zh) 西羅莫司及其衍生物的絡合物、其製備方法以及含有其的藥物組合物
PH12016502249A1 (en) Pladienolide pyridine compounds and methods of use
EA201791560A1 (ru) Порошковый состав для интраназального введения для лечения гипогликемии
ECSP16084317A (es) Formulaciones farmacéuticas, procesos para la preparación y métodos de uso
MX2016012835A (es) Composiciones y metodos para tratar las espinillas.
IN2014MU00303A (es)
MX2017015936A (es) Nueva composicion farmaceutica que comprende agentes tensioactivos no ionicos.
TN2018000188A1 (en) Isoindole compounds
NZ728401A (en) High purity oritavancin and method of producing same
MY186134A (en) Curcumin-peptide conjugates and formulations thereof
MX2022014792A (es) Cocristales, composiciones farmaceuticas de los mismos y metodos de tratamiento que los implican.
EA201700356A1 (ru) Новые циклопропанбензофуранилпиридопиразиндионы
IN2014MU00916A (es)
MX2018011422A (es) Farmaco de sal cristalina de clorhidrato para tratar o prevenir enfermedad asociada con janus cinasas (jak) y su metodo de preparacion.
MX2017002544A (es) Derivados de isoquinolinona utiles en el tratamiento contra el cancer.
WO2016073493A3 (en) Antifibrinolytic compounds